Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma.

J Invest Dermatol · 2015 · PMC4289407 · PMID 25148578

Europe PMC DOI

hedged sentence

0.0590

closest p · 1.2× alpha

0.0590

boldest claim

The sentences

did not reach statistical significancep=0.059so close (0.05 < p ≤ 0.1)

TP53 mutations were also more common in cutaneous and unknown primary melanomas, but this differential distribution did not reach statistical significance (p=0.059).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.